In the U.S. today, seven of the 10 leading causes of disability are caused by central nervous system (CNS) disorders. This has significantly accelerated the race to discover and develop novel medicines for patients suffering from these diseases.
Fortunately, Big Pharma has the resources to invest heavily in this space and is continuously investigating new ways to attack CNS disorders. How do we properly capture this expertise and forge valuable partnerships to gain a significant competitive advantage? What type of science compels the interest of Big Pharma investment? Which emerging partnership models are paying dividends, and what could be done differently? In this panel, three companies discuss tips and tricks for gaining Big Pharma’s attention, building strategic partnerships and the keys to success in working together once a partnership is secured.
Ability Level: Intermediate
Session ID: 21105